2023
Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssaysOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger studyComparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study
Holmer A, Luo J, Russ K, Park S, Yang J, Ertem F, Dueker J, Nguyen V, Hong S, Zenger C, Axelrad J, Sofia A, Petrov J, Al-Bawardy B, Fudman D, Llano E, Dailey J, Jangi S, Khakoo N, Damas O, Barnes E, Scott F, Ungaro R, Singh S, Helping-IBD R. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clinical Gastroenterology And Hepatology 2023, 21: 1598-1606.e5. PMID: 36642291, DOI: 10.1016/j.cgh.2023.01.002.Peer-Reviewed Original ResearchConceptsNon-TNF biologicsInflammatory bowel diseaseProgression-free survivalRecurrence-free survivalTNFα antagonistsActive cancerPrior cancerCohort studyBiologic agentsBowel diseaseRecent cancerMulticenter retrospective cohort studyMulti-center cohort studyIBD disease severityRetrospective cohort studyChoice of biologicsTumor necrosis factorCohort BPrimary outcomeComparable safetyΑ antagonistsComparative safetyCancer recurrenceNecrosis factorPatients
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2019
Patient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study
Al-Bawardy B, Kamboj AK, Desai S, Gorospe E, Bruining DH, Gostout CJ, Hansel SL, Larson MV, Murray JA, Nehra V, Leggett CL, Szarka LA, Watson RE, Rajan E. Patient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study. Scandinavian Journal Of Gastroenterology 2019, 54: 662-665. PMID: 31034255, DOI: 10.1080/00365521.2019.1608465.Peer-Reviewed Original ResearchConceptsPatient-oriented educationVideo capsule endoscopyCapsule passageWB groupCapsule retentionProcedure-related risksSignificant differencesLack of visualizationBACKGROUND/Information bookletPatientsVerbal educationCapsule endoscopyStudy teamWrist bandInterventionGroupStatusPOE groupEndoscopyPoor indicatorAid interventionsDifferences
2018
Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice
Maldonado FJ, Bawardy BF, Nehra AK, Lee YS, Bruining DH, Adkins MC, Keaveny TM, Johnson MP, Fidler JL, McCollough CH, Fletcher JG. Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice. Inflammatory Bowel Diseases 2018, 25: 1072-1079. PMID: 30476314, DOI: 10.1093/ibd/izy341.Peer-Reviewed Original ResearchConceptsBiomechanical CT analysisBone mineral densityHigh fracture riskHigh-risk groupFracture riskCT enterographyIBD patientsFemoral neck bone mineral densityInflammatory bowel disease patientsNeck bone mineral densityWorld Health Organization classificationConsecutive IBD patientsFracture risk classificationBowel disease patientsFindings of CTMetabolic bone diseaseRetrospective reviewClinical featuresExact prevalenceDisease patientsOrganization classificationMineral densityBone diseasePatientsClinical practiceVedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases 2018, 24: 2272-2277. PMID: 29718223, DOI: 10.1093/ibd/izy133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsBiological TherapyColitis, UlcerativeCrohn DiseaseFemaleFollow-Up StudiesGastrointestinal AgentsHumansInterferon-gamma Release TestsLatent TuberculosisMaleMycobacterium tuberculosisPrognosisProspective StudiesRetrospective StudiesTreatment OutcomeTuberculin TestConceptsLatent tuberculosis infectionInflammatory bowel diseaseTuberculin skin testBiologic therapyLTBI treatmentIBD patientsTuberculosis reactivationBowel diseaseTuberculosis infectionLTBI treatment regimenReactivation of TBRisk of reactivationInterferon-gamma releaseOutcome of treatmentStudy inclusion criteriaMedian annual riskAdalimumab monotherapyIsoniazid therapyTB reactivationCertolizumab pegolPrimary outcomeRetrospective reviewTreatment regimenMedian timeGamma releaseOutcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia
Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Prabhu-Coelho N, Larson MV, Wong Kee Song LM, Rajan E. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointestinal Endoscopy 2018, 88: 55-61. PMID: 29408558, DOI: 10.1016/j.gie.2018.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCause of DeathCohort StudiesComorbidityEndoscopy, GastrointestinalErythrocyte TransfusionFemaleGastrointestinal HemorrhageHematemesisHemostasis, SurgicalHumansHypotensionIntensive Care UnitsInternational Normalized RatioLiver CirrhosisLung DiseasesMaleMelenaMiddle AgedMortalityPartial Thromboplastin TimePlatelet TransfusionRecurrenceRetrospective StudiesRisk FactorsSeverity of Illness IndexThrombocytopeniaYoung AdultConceptsIncreased international normalized ratioOvert gastrointestinal bleedingInitial hemostasis rateRecurrent bleeding rateGastrointestinal bleedingLiver cirrhosisSevere thrombocytopeniaPlatelet transfusionsPlatelet countTherapeutic yieldRecurrent bleedingHemostasis rateAdverse eventsBleeding rateHigh initial hemostasis rateIntensive care unit admissionCare unit admissionPredictors of mortalityCause mortality ratesMedian platelet countHours of presentationInternational normalized ratioSetting of thrombocytopeniaProcedural adverse eventsPartial thromboplastin time
2017
Late-Onset Biallelic Mismatch Repair Deficiency Syndrome
Ebner DW, Al-Bawardy B, Sweetser S. Late-Onset Biallelic Mismatch Repair Deficiency Syndrome. Clinical Gastroenterology And Hepatology 2017, 16: e31-e32. PMID: 28602968, DOI: 10.1016/j.cgh.2017.05.039.Peer-Reviewed Case Reports and Technical Notes
2016
Outcomes of double-balloon enteroscopy-assisted direct percutaneous endoscopic jejunostomy tube placement
Al-Bawardy B, Gorospe EC, Alexander JA, Bruining DH, Coelho-Prabhu N, Rajan E, Wong Kee Song LM. Outcomes of double-balloon enteroscopy-assisted direct percutaneous endoscopic jejunostomy tube placement. Endoscopy 2016, 48: 552-556. PMID: 26964079, DOI: 10.1055/s-0042-101853.Peer-Reviewed Original ResearchConceptsJejunostomy tube placementAdverse eventsTube placementPost-procedural adverse eventsStudy aimDPEJ tube placementSerious adverse eventsSignificant adverse eventsMean procedure durationDouble-balloon enteroscopyTechnical success ratePatient demographicsCommon indicationSurgical repairGastric interpositionTechnical successMedical recordsProcedure durationLarge cohortDPEJSurgical adhesionsGut anatomyPatientsConventional endoscopyLarge series
2015
Retained Capsule Endoscopy in a Large Tertiary Care Academic Practice and Radiologic Predictors of Retention
Al-Bawardy B, Locke G, Huprich JE, Fletcher JG, Fidler JL, Barlow JM, Becker B, Rajan E, Loftus EV, Bruining DH, Hansel SL. Retained Capsule Endoscopy in a Large Tertiary Care Academic Practice and Radiologic Predictors of Retention. Inflammatory Bowel Diseases 2015, 21: 2158-2164. PMID: 26284295, DOI: 10.1097/mib.0000000000000482.Peer-Reviewed Original ResearchConceptsCapsule retentionCE retentionPartial obstructionCross-sectional imaging findingsHigh-risk featuresObscure gastrointestinal bleedingPresence of stricturesTertiary care populationComputed tomography scanComputed tomography reportsTreatment of inflammationCapsule endoscopy examinationSmall bowel anastomosisDetails of managementCE indicationsGastrointestinal bleedingObstructive symptomsRadiologic predictorsPatient demographicsCommon indicationGastrointestinal radiologistsRetrospective reviewClinical outcomesHeterogenous cohortImaging findings
2011
Missing cohort: Inflammatory bowel disease patients at increased risk for cervical dysplasia may be undervaccinated for HPV
Al-Bawardy B, Fine S, LaFond J, Doran A, Borum ML. Missing cohort: Inflammatory bowel disease patients at increased risk for cervical dysplasia may be undervaccinated for HPV. Inflammatory Bowel Diseases 2011, 18: 797-797. PMID: 22180343, DOI: 10.1002/ibd.21660.Peer-Reviewed Original Research